Related Experiment Video
Updated: May 4, 2026
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
B Jansen1, H Schlagbauer-Wadl, B D Brown
1Department of Clinical Pharmacology, University of Vienna, Austria.
Abstract:
Malignant melanoma is a prime example of cancers that respond poorly to various treatment modalities including chemotherapy. A number of chemotherapeutic agents have been shown recently to act by inducing apoptosis, a type of cell death antagonized by the bcl-2 gene. Human melanoma expresses Bcl-2 in up to 90% of all cases. In the present study we demonstrate that bcl-2 antisense oligonucleotide treatment improves the chemosensitivity of human melanoma grown in severe combined immunodeficient (SCID) mice. Our findings suggest that reduction of Bcl-2 in melanoma, and possibly also in a variety of other tumors, may be a novel and rational approach to improve chemosensitivity and treatment outcome.
Insights
Bcl-2 gene inhibition using antisense oligonucleotides enhanced chemotherapy effectiveness in human melanoma models. This suggests targeting Bcl-2 could improve cancer treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant melanoma often shows poor response to chemotherapy.
- The bcl-2 gene inhibits apoptosis, a programmed cell death pathway.
- Human melanoma frequently expresses Bcl-2 protein (up to 90% of cases).
Purpose of the Study:
- To investigate the effect of bcl-2 antisense oligonucleotide treatment on melanoma chemosensitivity.
- To determine if reducing Bcl-2 expression can enhance the efficacy of chemotherapy in human melanoma.
Main Methods:
- Treatment of human melanoma xenografts in severe combined immunodeficient (SCID) mice.
- Administration of bcl-2 antisense oligonucleotides to reduce Bcl-2 expression.
- Assessment of changes in chemosensitivity and treatment outcome.
Main Results:
- Bcl-2 antisense oligonucleotide treatment significantly improved the chemosensitivity of human melanoma.
- Reduction of Bcl-2 expression led to better response to chemotherapy in the studied models.
Conclusions:
- Targeting the bcl-2 gene with antisense oligonucleotides is a promising strategy to enhance chemotherapy effectiveness in melanoma.
- Reducing Bcl-2 may represent a novel approach to improve treatment outcomes for melanoma and potentially other cancers.
